ABBOTT LABORATORIES ABT 73.6
Health Care · NYSE · Data as of 2026-04-29
ABBOTT LABORATORIES (ABT) has delivered +7.7% annualized revenue growth, +30.5% earnings growth, and +11.7% dividend growth over 10 years of data. Ranked #195 of 1968 stocks overall and #18 of 260 in the Health Care sector by Steady Score.
About ABBOTT LABORATORIES
Company Overview
Abbott Laboratories develops healthcare products across diagnostics, medical devices, nutrition and established pharmaceuticals. Its offerings include laboratory and rapid tests, glucose-monitoring systems, cardiovascular devices, infant and adult nutrition, and branded generic medicines in emerging markets. Hospitals, laboratories, physicians, pharmacies and consumers use Abbott products for diagnosis, treatment, disease management and daily nutrition worldwide.
Read more
Business Model & Revenue
Abbott earns revenue from instruments, tests, implanted and wearable devices, nutritional products and medicines. Diagnostic instruments often create repeat demand for proprietary assays and consumables, while devices may be purchased per procedure or replaced over time. Four reportable segments reflect the portfolio. Procedure volumes, testing demand, product launches, reimbursement, retail consumption and foreign exchange influence revenue and margins.
Key Facts & Market Position
The company combines consumer-scale nutrition with regulated clinical technologies. Continuous glucose monitoring is a major device platform, while diagnostics spans centralized laboratories and point-of-care testing. Broad geographic and product exposure reduces reliance on a single therapy, but quality systems, clinical evidence, regulatory approvals and reliable high-volume manufacturing remain essential across the portfolio.